Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational therapeutic for the treatment of hereditary ATTR amyloidosis, will be presented at the 16th International Symposium on Amyloidosis , being held March 26-29, 2018 in Kumamoto, Japan.

For many people living with a rare disease, such as hereditary ATTR amyloidosis, it can take years to be accurately diagnosed. Moreover, many may not realize that the symptoms they are experiencing can be tied to their family health history.

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that Sanofi Genzyme has declined its opt-in for the development and commercialization of lumasiran , an investigational RNAi therapeutic for the treatment of Primary Hyperoxaluria Type 1 .

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) could become a player in the emerging field of small RNA interference, or RNAi, according to Chardan Capital Markets. The Analyst Chardan analyst Keay Nakae ...

The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

The Cambridge, Massachusetts-based company said it had a loss of $1.48 per share. The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2017 and highlighted recent progress in advancing its pipeline.